Please use this identifier to cite or link to this item:
|Title:||Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B|
|Keywords:||Chronic hepatitis B|
|Citation:||Zeuzem, S., Gane, E., Liaw, Y.-F., Lim, S.G., DiBisceglie, A., Buti, M., Chutaputti, A., Rasenack, J., Hou, J., O'Brien, C., Nguyen, T.T., Jia, J., Poynard, T., Belanger, B., Bao, W., Naoumov, N.V. (2009-07). Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. Journal of Hepatology 51 (1) : 11-20. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jhep.2008.12.019|
|Abstract:||Background/Aims: In the GLOBE trial, telbivudine treatment was identified as a significant, independent predictor of better outcomes at 2 years. We analyzed all telbivudine recipients in this trial to determine the predictors of optimal outcomes. Methods: The intent-to-treat population comprised 458 HBeAg-positive and 222 HBeAg-negative telbivudine-treated patients. Multivariate logistic regression analyses were employed to evaluate baseline and/or early on-treatment variables. Results: Baseline HBV DNA < 9 log10 copies/mL, or ALT levels ≥2× above normal were strong pretreatment predictors for HBeAg-positive, but not for HBeAg-negative patients. However, non-detectable serum HBV DNA at treatment week 24 (TW24) was the strongest predictor for better outcomes for both groups. A combination of pretreatment characteristics plus TW24 response identified subgroups with the best outcomes: (1) HBeAg-positive patients with baseline HBV DNA < 9 log10 copies/mL, ALT ≥ 2× above normal and non-detectable HBV DNA at TW24 achieved at 2 years: non-detectable HBV DNA in 89%, HBeAg seroconversion in 52%, telbivudine resistance in 1.8%; and (2) HBeAg-negative patients with baseline HBV DNA < 7 log10 copies/mL and non-detectable serum HBV DNA at TW24 achieved at 2 years: non-detectable HBV DNA in 91%, telbivudine resistance in 2.3%. Conclusion: During telbivudine treatment, non-detectable serum HBV DNA at treatment week 24 is the strongest predictor for optimal outcomes at 2 years. © 2009 European Association for the Study of the Liver.|
|Source Title:||Journal of Hepatology|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Aug 16, 2018
WEB OF SCIENCETM
checked on Jul 24, 2018
checked on Aug 9, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.